3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
25
Observational
3
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Blood Specimen Collection
131
Surveys and Questionnaires
130
Specimen Handling
57
Observation
55
Radiotherapy
44
Interviews as Topic
34
Surgical Procedures, Operative
32
Drug Therapy
31
Biopsy
28
Data Collection
26
Magnetic Resonance Spectroscopy
25
Nivolumab
20
Watchful Waiting
20
Immune Checkpoint Inhibitors
18
Immunotherapy
17
Magnetic Resonance Imaging
17
Therapeutics
17
Standard of Care
16
trastuzumab deruxtecan
14
Liquid Biopsy
13
Tomography, X-Ray Computed
13
palbociclib
13
Hematologic Tests
12
Restraint, Physical
12
Focus Groups
11
Genetic Testing
11
Bevacizumab
10
Positron Emission Tomography Computed Tomography
10
darolutamide
10
enzalutamide
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Observational
×
asciminib
×
1 year
×
Clear all
NCT06092879
2026-05-29
ASSURE-3
Novartis
Active not recruiting
201 enrolled
NCT05943522
2026-04-20
Asciminib RMP Study
Novartis
Recruiting
600 enrolled
NCT07091019
2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
1,000 enrolled